In a filing, Akero Therapeutics Inc revealed its Chief Development Officer Yale Catriona unloaded Company’s shares for reported $0.15 million on Sep 20 ’24. In the deal valued at $27.65 per share,5,500 shares were sold. As a result of this transaction, Yale Catriona now holds 75,294 shares worth roughly $2.16 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Yale Catriona sold 3,871 shares, generating $106,685 in total proceeds. Upon selling the shares at $27.56, the Chief Development Officer now owns 75,294 shares.
Before that, Yale Catriona sold 2,485 shares. Akero Therapeutics Inc shares valued at $68,375 were divested by the Chief Development Officer at a price of $27.52 per share. As a result of the transaction, Yale Catriona now holds 75,294 shares, worth roughly $2.16 million.
A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in mid September with a ‘”an Overweight”‘ rating. UBS began covering AKRO with “Buy” recommendation on August 28, 2023. Morgan Stanley revised its rating on January 27, 2023. It rated AKRO as “an Overweight” which previously was an “an Equal-weight”.
Price Performance Review of AKRO
On Monday, Akero Therapeutics Inc [NASDAQ:AKRO] saw its stock jump 1.59% to $28.69. Over the last five days, the stock has gained 1.13%. Akero Therapeutics Inc shares have risen nearly 22.87% since the year began. Nevertheless, the stocks have fallen -40.48% over the past one year. While a 52-week high of $51.24 was reached on 03/04/24, a 52-week low of $11.25 was recorded on 02/06/24. SMA at 50 days reached $26.48, while 200 days put it at $23.77.
Levels Of Support And Resistance For AKRO Stock
The 24-hour chart illustrates a support level at 27.99, which if violated will result in even more drops to 27.29. On the upside, there is a resistance level at 29.25. A further resistance level may holdings at 29.82. The Relative Strength Index (RSI) on the 14-day chart is 60.54, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.20, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 24.28%. Stochastics %K at 78.84% indicates the stock is a holding.
How much short interest is there in Akero Therapeutics Inc?
A steep rise in short interest was recorded in Akero Therapeutics Inc stocks on 2024-09-13, dropping by 30211.0 shares to a total of 7.16 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-15 was 7.19 million shares. There was a decline of -0.42%, which implies that there is a negative sentiment for the stock.
